Disease course, treatments, and outcomes of children with systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD).
Yannan HuangLaura Sompii-MontgomeryJessie PattiAlex PickeringShima YasinThuy DoElizabeth BakerDenny GaoRaheh Abdul-AzizEdward M BehrensScott W CannaMatthew ClarkDominic O CoKathleen P CollinsBarbara EberhardMonica FriedmanThomas B GrahamTimothy HahnAimee O HershPatricia HobdayMichael J HollandJennifer HugginsPai-Yue LuMelissa L MannionCynthia K ManosJessica NeelyKaren OnelAmir B OrandiAndrea RamirezAdam ReinhardtMona RiskallaLaisa SantiagoMatthew L StollTracy TingAlexei A GromChris ToweGrant S SchulertPublished in: Arthritis care & research (2023)
Patients with SJIA-LD had highly varied courses, with lower mortality than previously reported but frequent hypoxia and requirement for respiratory support. Treatment strategies were highly varied, highlighting an urgent need for focused clinical trials.
Keyphrases
- juvenile idiopathic arthritis
- clinical trial
- disease activity
- young adults
- cardiovascular events
- endothelial cells
- risk factors
- randomized controlled trial
- systemic lupus erythematosus
- adipose tissue
- type diabetes
- phase ii
- metabolic syndrome
- respiratory tract
- insulin resistance
- open label
- glycemic control
- skeletal muscle
- drug induced
- weight loss